FDA approves Sanofi’s Infilbray as first treatment for Type 3 Gaucher neurological symptoms on November 19, 2026 Approved Gaucher Disease, Type 3 (disorder) Infilbray LEAP2MONO sanofi United States Food and Drug Administration +